Consensus and controversies regarding the treatment of rhabdomyosarcoma.
Scott C BorinsteinDiana SteppanMasanori HayashiDavid M LoebMichael S IsakoffOdion BinitieAndrew S BrohlJulia A BridgeMark StavasEric T ShinoharaWilliam H MeyerDamon R ReedLars M WagnerPublished in: Pediatric blood & cancer (2017)
Optimal treatment of rhabdomyosarcoma (RMS) requires multidisciplinary approach, incorporating chemotherapy with local control. Although current therapies are built on cooperative group trials, a comprehensive standard of care to guide clinical decision making has been lacking, especially for relapsed patients. Therefore, we assembled a panel of pediatric and adolescent and young adult sarcoma experts to develop treatment guidelines for managing RMS and to identify areas in which further research is needed. We created algorithms incorporating evidence-based care for patients with RMS, emphasizing the importance of clinical trials and close integration of all specialties involved in the care of these patients.
Keyphrases
- end stage renal disease
- healthcare
- young adults
- clinical trial
- palliative care
- ejection fraction
- newly diagnosed
- decision making
- quality improvement
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- squamous cell carcinoma
- clinical practice
- acute lymphoblastic leukemia
- machine learning
- randomized controlled trial
- patient reported outcomes
- acute myeloid leukemia
- mental health
- deep learning
- chronic pain
- study protocol
- phase iii